SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home ...
(RTTNews) - ResMed Inc.(RMD), announced Thursday that its NightOwl home sleep apnea test or HSAT is now available across the United States, providing a simple and effective at-home diagnostic solution ...
Resmed has received clearance from the U.S. Food and Drug Administration (FDA) for an artificial intelligence (AI)-enabled ...
Resmed believes its artificial intelligence-powered approach to personalizing the settings of its connected CPAP machines can lead to better sleep for people with obstructive apnea. | Resmed believes ...
As Philips reaches a consent decree agreement with the FDA that will temporarily suspend its sales of sleep therapy devices in the U.S., competitor ResMed, meanwhile, is ramping up its product ...
Resmed (NYSE: RMD) announced today that it received FDA clearance for its Smart Comfort personalized therapy comfort settings ...
Analysts expect a negative impact on ResMed Inc. (RMD) after privately held pharmaceutical company and rival Apnimed, Inc. announced positive results from its late-stage clinical trial evaluating the ...
Connected sleep devicemaker ResMed today released the AirSense 11, its latest CPAP machine iteration, which includes a host of new features to treat obstructive sleep apnea. The new machine has many ...
For the past 18 months, ResMed Chief Executive Mick Farrell has been publicly outspoken in urging that medical devices get priority access to semiconductors amid global chip shortages coming out of ...
ResMed is potentially undervalued, trading at a 31.65% discount from its 5Y average P/E ratio, with strong market leadership and untapped growth potential in OSA treatment. Projected 10-year EPS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback